The development and study of new molecules with dual, triple, or quadruple action targeting GLP-1, GIP, glucagon, and IGF-1 is important to cover as many pathogenic links of obesity with as few adverse effects as possible. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.